News

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy.
Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...
The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...
An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination ...
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...
Records show that a top U.S. regulator rejected the recommendations of agency experts and limited the use of Covid vaccines.
Professor Hirohide Saito (Department of Life Science Frontiers at CiRA / The University of Tokyo) and Assistant Professor ...
Two young elephants at the Cincinnati Zoo, Sanjay and Kabir, overcame a deadly virus thanks to a new vaccine introduced to ...